. 2022 Feb 9;40(2):269–279. doi: 10.1002/hon.2964

TABLE 1.

Median model‐predicted probabilities of treatment‐emergent Grade ≥3 neutropenia for venetoclax plus HMA or placebo plus AZA

Race	N	Median exposure (AUC_ss) at 400 mg venetoclax (µg*day/ml)	Predicted probability (%) for PBO + AZA	Predicted probability (%) for VEN 400 mg + HMA	Difference (%) between VEN + HMA and PBO + AZA	P‐value ^a
Non‐Asian	464 ^b	1.11	36.4	61.0	24.6	‐‐
Asian	111	1.85	64.4	84.9	20.5	0.98

Abbreviations: AZA, azacitidine; HMA, hypomethylating agent; PBO, placebo; VEN, venetoclax.

^{^a}

Effect of Asian race on E _max parameter (venetoclax effect) in final model.

^{^b}

Includes 5 subjects with missing race information.